Recent advances in lanthipeptide biosynthesis-A review

doi:10.13343/j.cnki.wsxb.20150427

Home > Archive>Volume 56, Issue 3, 2016 >373-382. DOI:10.13343/j.cnki.wsxb.20150427

Recent advances in lanthipeptide biosynthesis-A review
DOI:
                        10.13343/j.cnki.wsxb.20150427
                    
CSTR:
                        32112.14.j.AMS.20150427
                    
Author:
                        Tianlu MoTianlu Mo
School of Chemical and Biological Engineering, Lanzhou Jiaotong University, Lanzhou 730070, Gansu Province, China;Department of Chemistry, Fudan University, Shanghai 200433, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
Lingui XueLingui Xue
School of Chemical and Biological Engineering, Lanzhou Jiaotong University, Lanzhou 730070, Gansu Province, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
Qi ZhangQi Zhang
Department of Chemistry, Fudan University, Shanghai 200433, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:
Clc Number:
Fund Project:

Article

Figures

Metrics

Reference [35]

Related [20]

Cited by

Materials

Comments

Abstract:

Lanthipeptides are a growing class of ribosomally synthesized and posttranslationally modified peptide (RiPP) natural products. These compounds are widely distributed among taxonomically distant species, and their structures and biological activities are diverse, providing an important source for drug research and developement. In this review, we summarized the recent advances in the understanding of structure, classification, evolution and substrate-controlled biosynthetic mechanism of lanthipeptide, attempting to highlight the intriguing chemistry and enzymology in the biosynthesis of this growing family of natural products.

Key words:lanthipeptide;RiPP;substrate-controlled;antibacterial activity;stereoselectivity

Reference

[1] Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJT, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Natural Product Reports, 2013, 30(1): 108-160.

[2] Velásquez JE, van der Donk WA. Genome mining for ribosomally synthesized natural products. Current Opinion in Chemical Biology, 2011, 15(1): 11-21.

[3] Chatterjee C, Paul M, Xie LL, van der Donk WA. Biosynthesis and mode of action of lantibiotics. Chemical Reviews, 2005, 105(2): 633-684.

[4] Knerr PJ, van der Donk WA. Discovery, biosynthesis, and engineering of lantipeptides. Annual Review of Biochemistry, 2012, 81(1): 479-505.

[5] Gross E, Morell JL. Structure of nisin. Journal of the American Chemical Society, 1971, 93(18): 4634-4635.

[6] Rogers LA. The inhibiting effect of Streptococcus lactis on Lactobacillus bulgaricus. Journal of Bacteriology, 1928, 16(5): 321-325.

[7] Delves-Broughton J, Blackburn P, Evans RJ, Hugenholtz J. Applications of the bacteriocin, nisin. Antonie van Leeuwenhoek, 1996, 69(2): 193-202.

[8] Piper C, Cotter PD, Ross RP, Hill C. Discovery of medically significant lantibiotics. Current Drug Discovery Technologies, 2009, 6(1): 1-18.

[9] Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chemistry & Biology, 2008, 15(1): 22-31.

[10] Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. Journal of Antimicrobial Chemotherapy, 2013, 68(1): 168-176.

[11] Hillman JD. Genetically modified Streptococcus mutans for the prevention of dental caries. Antonie van Leeuwenhoek, 2002, 82(1-4): 361-366.

[12] Märki F, Hänni E, Fredenhagen A, van Oostrum J. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin B and C, and cinnamycin as indirect inhibitors of phospholipase A2. Biochemical Pharmacology, 1991, 42(10): 2027-2035.

[13] Grasemann H. New developments in pharmaceutical treatments for cystic fibrosis. Current Pharmaceutical Design, 2012, 18(5): 613.

[14] Krawczyk JM, Völler GH, Krawczyk B, Kretz J, Brönstrup M, Süssmuth RD. Heterologous expression and engineering studies of labyrinthopeptins, class III lantibiotics from Actinomadura namibiensis. Chemistry & Biology, 2013, 20(1): 111-122.

[15] Férir G, Petrova MI, Andrei G, Huskens D, Hoorelbeke B, Snoeck R, Vanderleyden J, Balzarini J, Bartoschek S, Brönstrup M, Süssmuth RD, Schols D. The lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applications. PLoS One, 2013, 8(5): e64010.

[16] Iorio M, Sasso O, Maffioli SI, Bertorelli R, Monciardini P, Sosio M, Bonezzi F, Summa M, Brunati C, Bordoni R, Corti G, Tarozzo G, Piomelli D, Reggiani A, Donadio S. A glycosylated, labionin-containing lanthipeptide with marked antinociceptive activity. ACS Chemical Biology, 2014, 9(2): 398-404.

[17] Sit CS, Yoganathan S, Vederas JC. Biosynthesis of aminovinyl-cysteine-containing peptides and its application in the production of potential drug candidates. Accounts of Chemical Research, 2011, 44(4): 261-268.

[18] Claesen J, Bibb M. Genome mining and genetic analysis of cypemycin biosynthesis reveal an unusual class of posttranslationally modified peptides. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(37): 16297-16302.

[19] Willey JM, van der Donk WA. Lantibiotics: peptides of diverse structure and function. Annual Review of Microbiology, 2007, 61(1): 477-501.

[20] Breukink E, Wiedemann I, van Kraaij C, Kuipers OP, Sahl HG, de Kruijff B. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science, 1999, 286(5448): 2361-2364.

[21] Oman TJ, Lupoli TJ, Wang TSA, Kahne D, Walker S, van der Donk WA. Haloduracin α binds the peptidoglycan precursor lipid II with 2: 1 stoichiometry. Journal of the American Chemical Society, 2011, 133(44): 17544-17547.

[22] Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG. Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrobial Agents and Chemotherapy, 1995, 39(3): 714-719.

[23] Tang WX, Jiménez-Osés G, Houk KN, van der Donk WA. Substrate control in stereoselective lanthionine biosynthesis. Nature Chemistry, 2015, 7(1): 57-64.

[24] Tang WX, van der Donk WA. The sequence of the enterococcal cytolysin imparts unusual lanthionine stereochemistry. Nature Chemical Biology, 2013, 9(3): 157-159.

[25] Müller WM, Schmiederer T, Ensle P, Süssmuth RD. In vitro biosynthesis of the prepeptide of type-III lantibiotic labyrinthopeptin A2 including formation of a C-C bond as a post-translational modification. Angewandte Chemie International Edition, 2010, 49(13): 2436-2440.

[26] Ortega MA, Hao Y, Zhang Q, Walker MC, van der Donk WA, Nair SK. Structure and mechanism of the tRNA-dependent lantibiotic dehydratase NisB. Nature, 2015, 517(7535): 509-512.

[27] Li B, Yu JPJ, Brunzelle JS, Moll GN, van der Donk WA, Nair SK. Structure and mechanism of the lantibiotic cyclase involved in nisin biosynthesis. Science, 2006, 311(5766): 1464-1467.

[28] Yu Y, Zhang Q, van der Donk WA. Insights into the evolution of lanthipeptide biosynthesis. Protein Science, 2013, 22(11): 1478-1489.

[29] Zhang Q, Yu Y, Vélasquez JE, van der Donk WA. Evolution of lanthipeptide synthetases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(45): 18361-18366.

[30] Dong SH, Tang WX, Lukk T, Yu Y, Nair SK, van der Donk WA. The enterococcal cytolysin synthetase has an unanticipated lipid kinase fold. eLife, 2015, 4: e07607.

[31] Wang H, van der Donk WA. Biosynthesis of the class III lantipeptide catenulipeptin. ACS Chemical Biology, 2012, 7(9): 1529-1535.

[32] Zhang Q, Doroghazi JR, Zhao XL, Walker MC, van der Donk WA. Expanded natural product diversity revealed by analysis of lanthipeptide-like gene clusters in Actinobacteria. Applied and Environmental Microbiology, 2015, 81(13): 4339-4350.

[33] Li B, Sher D, Kelly L, Shi YX, Huang K, Knerr PJ, Joewono I, Rusch D, Chisholm SW, van der Donk WA. Catalytic promiscuity in the biosynthesis of cyclic peptide secondary metabolites in planktonic marine cyanobacteria. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(23): 10430-10435.

[34] Zhang Q, Yang X, Wang H, van der Donk WA. High divergence of the precursor peptides in combinatorial lanthipeptide biosynthesis. ACS Chemical Biology, 2014, 9(11): 2686-2694.

[35] Ding W, Li YZ, Zhang Q. Substrate-controlled stereochemistry in natural product biosynthesis. ACS Chemical Biology, 2015, 10(7): 1590-1598.

Get Citation

Tianlu Mo, Lingui Xue, Qi Zhang. Recent advances in lanthipeptide biosynthesis-A review. [J]. Acta Microbiologica Sinica, 2016, 56(3): 373-382

Copy

Article Metrics

Abstract:
PDF:
HTML:
Cited by:

History

Received:September 16,2015
Revised:November 25,2015
Adopted:
Online: March 03,2016
Published:

Get Citation

Related Videos

Share

Article Metrics

History

Article QR Code